AIM: To determine if doxorubicin (Dox) alters hepatic proteome acetylation status and if acetylation status was associated with an apoptotic environment. METHODS: Doxorubicin (20 mg/kg; Sigma, Saint Louis, MO; n = 8) or NaCl (0.9%; n = 7) was administered as an intraperitoneal injection to male F344 rats, 6-wk of age. Once animals were treated with Dox or saline, all animals were fasted until sacrifice 24 h later. RESULTS: Dox treatment decreased proteome lysine acetylation likely due to a decrease in histone acetyltransferase activity. Proteome deacetylation may likely not be associated with a proapoptotic environment. Dox did not increase caspase-9, -8, or -3 activation nor poly (adenosine diphosphate-ribose) polymerase-1 cleavage. Dox did stimulate caspase-12 activation, however, it likely did not play a role in apoptosis induction. CONCLUSION: Early effects of Dox involve hepatic proteome lysine deacetylation and caspase-12 activation under these experimental conditions.
AIM: To determine if doxorubicin (Dox) alters hepatic proteome acetylation status and if acetylation status was associated with an apoptotic environment. METHODS:Doxorubicin (20 mg/kg; Sigma, Saint Louis, MO; n = 8) or NaCl (0.9%; n = 7) was administered as an intraperitoneal injection to male F344 rats, 6-wk of age. Once animals were treated with Dox or saline, all animals were fasted until sacrifice 24 h later. RESULTS:Dox treatment decreased proteome lysine acetylation likely due to a decrease in histone acetyltransferase activity. Proteome deacetylation may likely not be associated with a proapoptotic environment. Dox did not increase caspase-9, -8, or -3 activation nor poly (adenosine diphosphate-ribose) polymerase-1 cleavage. Dox did stimulate caspase-12 activation, however, it likely did not play a role in apoptosis induction. CONCLUSION: Early effects of Dox involve hepatic proteome lysine deacetylation and caspase-12 activation under these experimental conditions.
Authors: Katherine Labbé; Jenny Miu; Garabet Yeretssian; Lena Serghides; Mifong Tam; Constance A Finney; Laura K Erdman; Marie-Line Goulet; Kevin C Kain; Mary M Stevenson; Maya Saleh Journal: J Immunol Date: 2010-09-27 Impact factor: 5.422
Authors: M Cem Koçkar; Mustafa Nazıroğlu; Omer Celik; H Tahsin Tola; Dilek Bayram; Ahmet Koyu Journal: Cell Biochem Funct Date: 2010-11-08 Impact factor: 3.685
Authors: Elena J Ladas; Judith S Jacobson; Deborah D Kennedy; Katherine Teel; Aaron Fleischauer; Kara M Kelly Journal: J Clin Oncol Date: 2004-02-01 Impact factor: 44.544
Authors: Sui Zhang; Xiaobing Liu; Tasneem Bawa-Khalfe; Long-Sheng Lu; Yi Lisa Lyu; Leroy F Liu; Edward T H Yeh Journal: Nat Med Date: 2012-10-28 Impact factor: 53.440
Authors: April C Childs; Sharon L Phaneuf; Amie J Dirks; Tracey Phillips; Christiaan Leeuwenburgh Journal: Cancer Res Date: 2002-08-15 Impact factor: 12.701
Authors: Amy V Pointon; Tracy M Walker; Kate M Phillips; Jinli Luo; Joan Riley; Shu-Dong Zhang; Joel D Parry; Jonathan J Lyon; Emma L Marczylo; Timothy W Gant Journal: PLoS One Date: 2010-09-15 Impact factor: 3.240
Authors: J Matthew Hinkley; Aaron B Morton; Noriko Ichinoseki-Sekine; Andres Mor Huertas; Ashley J Smuder Journal: Med Sci Sports Exerc Date: 2019-06 Impact factor: 5.411